Shine the light on Sickle cell- Hydroxyurea in Sickle cell disease.
June 19 is observed as world Sickle cell disease and celebrated globally to raise awareness about Sickle cell disease. The theme is “Shine the light on Sickle cell”. In this post let me shine some light on “Hydroxyurea in Sickle cell disease”. Properties Hydroxyurea Drug class Antimetabolite Mechanism of action Inhibition of ribonucleotide reductase (RR) Increases HbF production Pharmacology Half-life :4 hours Potential benefits · Improved survival & increased life expectancy · Decreased venoocclusive pain · Decreased Acute coronary syndrome episodes · Decreased transfusions · Decreased priapism episodes · Preserve splenic function in infants · Improved quality of life and daily functioning Beneficial In HbSS or HBs/ Beta 0 thalassemia genotypes Standard indications – Can be given at any age from 6 month old infants to adults · Frequent pain crises · Acute chest syndrome · Severe or s